Keyword: Botox

Ex-Allergan executives raised $15.5 million for Bonti, a startup working on a unique botulinum neurotoxin.

The financing will position Evolus to challenge Allergan’s grip on the wrinkle-busting sector by bringing a biosimilar copy of Botox to market.

The effect of the neuromodulator on wrinkles lasted for six months, suggesting it poses a threat to Allergan’s blockbuster Botox franchise.

Check out the rest of Wednesday's news of note.

We delve into the R&D strategy for Allergan, a company that nearly became part of Pfizer last year.

The Californian biotech Dermira says its experimental sweat drug DRM04 passed one Phase III test but narrowly missed its target on a second--although analysts believe this will still be good enough to reap an FDA approval.